Xylem Inc. (NYSE:XYL)‘s stock had its “outperform” rating restated by Oppenheimer Holdings Inc. in a report issued on Monday. They presently have a $58.00 target price on the stock, up from their previous target price of $55.00. Oppenheimer Holdings Inc.’s price target points to a potential upside of 9.60% from the company’s current price.

Several other research analysts have also issued reports on the stock. Northcoast Research began coverage on shares of Xylem in a research report on Thursday, November 17th. They issued a “buy” rating for the company. Stifel Nicolaus increased their price target on shares of Xylem from $47.00 to $48.00 and gave the stock a “hold” rating in a research report on Wednesday, November 2nd. Janney Montgomery Scott raised shares of Xylem from a “neutral” rating to a “buy” rating and increased their price target for the stock from $50.00 to $52.00 in a research report on Wednesday, November 2nd. Atlantic Securities raised shares of Xylem from a “neutral” rating to an “overweight” rating and set a $54.00 price objective for the company in a report on Monday, August 22nd. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $50.00 price objective (up previously from $45.00) on shares of Xylem in a report on Tuesday, August 16th. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Xylem has a consensus rating of “Buy” and an average target price of $47.15.

Analyst Recommendations for Xylem (NYSE:XYL)

Shares of Xylem (NYSE:XYL) opened at 52.92 on Monday. The firm has a market capitalization of $9.49 billion, a P/E ratio of 29.37 and a beta of 1.18. The firm has a 50-day moving average price of $50.29 and a 200-day moving average price of $48.16. Xylem has a 52-week low of $31.67 and a 52-week high of $54.99.

Xylem (NYSE:XYL) last posted its quarterly earnings results on Tuesday, November 1st. The company reported $0.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.01. Xylem had a net margin of 8.83% and a return on equity of 16.38%. The firm earned $897 million during the quarter, compared to analyst estimates of $913.53 million. During the same quarter in the prior year, the business posted $0.49 earnings per share. The company’s quarterly revenue was down .6% compared to the same quarter last year. On average, equities research analysts anticipate that Xylem will post $2.04 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 7th. Shareholders of record on Wednesday, November 9th will be paid a $0.1549 dividend. The ex-dividend date of this dividend is Monday, November 7th. This represents a $0.62 dividend on an annualized basis and a yield of 1.17%. Xylem’s payout ratio is presently 34.44%.

In other Xylem news, SVP Claudia S. Toussaint sold 5,300 shares of the firm’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $47.27, for a total value of $250,531.00. Following the transaction, the senior vice president now directly owns 44,033 shares of the company’s stock, valued at $2,081,439.91. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Colin R. Sabol sold 27,473 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $50.91, for a total transaction of $1,398,650.43. Following the completion of the transaction, the insider now directly owns 65,530 shares in the company, valued at $3,336,132.30. The disclosure for this sale can be found here. 0.77% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in XYL. ETRADE Capital Management LLC purchased a new position in shares of Xylem during the third quarter worth $358,000. Scout Investments Inc. purchased a new position in shares of Xylem during the third quarter worth $27,492,000. Price T Rowe Associates Inc. MD boosted its position in shares of Xylem by 0.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 9,831,231 shares of the company’s stock worth $515,648,000 after buying an additional 40,520 shares in the last quarter. Quantitative Systematic Strategies LLC purchased a new position in shares of Xylem during the third quarter worth $548,000. Finally, Somerville Kurt F boosted its position in shares of Xylem by 1.6% in the third quarter. Somerville Kurt F now owns 77,688 shares of the company’s stock worth $4,074,000 after buying an additional 1,200 shares in the last quarter. 84.62% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Xylem Inc. (XYL) Stock Rating Reaffirmed by Oppenheimer Holdings Inc.” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/23/xylem-inc-xyl-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.

Xylem Company Profile

Xylem Inc is engaged in the design, manufacturing, and application of engineered technologies for the water industry. The Company is an equipment and service provider for water and wastewater applications with a portfolio of products and services addressing the cycle of water, from collection, distribution and use to the return of water to the environment.

5 Day Chart for NYSE:XYL

Receive News & Stock Ratings for Xylem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem Inc. and related stocks with our FREE daily email newsletter.